KP

Krishna Polu

CEO Commit Biologics

San Francisco Bay Area

VC
Investor

Invests in

Stages:

Seed
Pre-seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Clinical Development
Biotechnology
Cardiovascular Medicine
Pharmacovigilance
Risk Management
Nephrology
Oncology
FDA
Diabetes
Internal Medicine
Therapeutic Areas
Lifesciences
EDC
CRO
Medicine
Pharmaceutical Industry
Clinical Research
Pharmaceutical Sales
Neurology
Drug Development

Education

Investments

Bicara Therapeutics

Series B

Total Funding: $270M

Work Experience

Lupus Research Alliance

2024

  • Steering Committee Member, Venture Philanthropy

    2024

Commit Biologics

2023

  • Chief Executive Officer

    2023

Sardona Therapeutics

2023 - 2023

  • Director Board of Directors

    2023 - 2023

Bicara Therapeutics

2022 - 2023

  • Director Board of Directors

    2022 - 2023

Red Tree Venture Capital

2020 - 2023

  • Principal

    2020 - 2023

Frazier Lifesciences Acquisition Corporation

2020 - 2022

  • Director Board of Directors

    2020 - 2022

    Successful De-SPAC combo with New Amsterdam Pharma (NASDAQ:NAMS)

Equillium, Inc.

2018 - 2021

  • EVP of R&D and Chief Medical Officer

    2018 - 2021

Scout Bio

2018 - 2018

  • Interim CEO

    2018 - 2018

    Scout Bio, Inc., a newly-formed development-stage biotechnology company focused on the discovery and development of vector-delivered protein and monoclonal antibody therapeutics for animal health. https://www.scoutbio.co/

Frazier Healthcare Partners

2017 - 2018

  • Entrepreneur In Residence

    2017 - 2018

    CEO and Founder of Expedition Therapeutics, a Frazier Healthcare search company focused on identifying and in-licensing assets in the kidney, metabolic, and inflammatory therapeutic areas.

Raptor Pharmaceuticals

2015 - 2016

  • Chief Medical Officer

    2015 - 2016

    Acquired by Horizon Pharmaceuticals.